```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  AUG 05   New pricing for EUROPATFULL and PCTFULL effective
                   August 1, 2003
 NEWS  5  AUG 13   Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS  6  AUG 18   Data available for download as a PDF in RDISCLOSURE
 NEWS  7  AUG 18   Simultaneous left and right truncation added to PASCAL
 NEWS  8  AUG 18   FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                   Truncation
 NEWS  9  AUG 18   Simultaneous left and right truncation added to ANABSTR
 NEWS 10  SEP 22   DIPPR file reloaded
 NEWS 11  SEP 25   INPADOC: Legal Status data to be reloaded
 NEWS 12  SEP 29   DISSABS now available on STN
 NEWS 13  OCT 10   PCTFULL: Two new display fields added
 NEWS 14  OCT 21   BIOSIS file reloaded and enhanced
 NEWS 15  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS 16  NOV 24   MSDS-CCOHS file reloaded

 NEWS EXPRESS  NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:16:39 ON 05 DEC 2003

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'MEDLINE' ENTERED AT 08:17:09 ON 05 DEC 2003
```

FILE 'USPATFULL' ENTERED AT 08:17:09 ON 05 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 08:17:09 ON 05 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s atopic dermatitis
L1 62880 ATOPIC DERMATITIS

=> s MC148P
L2 6 MC148P

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 6 USPATFULL on STN
TI Atopic dermatitis treatment method
AB Compositions are provided for treating atopic dermatitis, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from Molluscum Contagiosum Virus (MCV), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of MCV proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other **MC148P** type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other **MC148P** type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to MCV proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:16613 USPATFULL		
TITLE:	Atopic dermatitis treatment method		
INVENTOR(S):	Paslin, David A., San Mateo, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		

LINE COUNT: 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -

AN AAU76904 Protein DGENE
AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. THe method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the molluscum contagiosum virus MC148 type 2 protein used in the method of the invention.

ACCESSION NUMBER: AAU76904 Protein DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: N-PSDB: ABK10280
DESCRIPTION: Molluscum contagiosum virus MCV148 type 2 protein.

App'l

L2 ANSWER 3 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -

AN AAU76903 Protein DGENE
AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. THe method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the molluscum contagiosum virus MC148 type I protein used in the method of the invention.

ACCESSION NUMBER: AAU76903 Protein DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: N-PSDB: ABK10279
DESCRIPTION: Molluscum contagiosum virus MCV148 type I protein.

L2 ANSWER 4 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -

AN ABK10280 DNA DGENE
AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. THe method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the cDNA encoding the molluscum contagiosum virus MC148 type 2 protein used in the method of the invention. This sequence corresponds to nucleotides 166,992 - 167,303 of the MCV genome.

ACCESSION NUMBER: ABK10280 DNA DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: P-PSDB: AAU76904
DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type 2 protein.

L2 ANSWER 5 OF 6 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -

AN ABK10279 DNA DGENE
AB This invention relates to a novel method for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. THe method comprises administering a molluscum contagiosum Virus **MC148P** protein (specifically MC148P1, MC148P2, MC148P3) **MC148P**. The method of the invention may have dermatological, anti-allergic, anti-inflammatory and anti-asthmatic activities. The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders. The present sequence represents the cDNA encoding the molluscum contagiosum virus MC148 type I protein used in the method of the invention. This sequence corresponds to nucleotides 166,992-167,303 of the MCV genome.

ACCESSION NUMBER: ABK10279 DNA DGENE
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus -
INVENTOR: Paslin D A
PATENT ASSIGNEE: (PASL-I) PASLIN D A.
PATENT INFO: US 2002009489 A1 20020124 16p
APPLICATION INFO: US 2001-920897 20010801
PRIORITY INFO: US 1999-426093 19991022
US 2000-624748 20000724
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2002-138958 [18]
CROSS REFERENCES: P-PSDB: AAU76903
DESCRIPTION: cDNA encoding molluscum contagiosum virus MCV148 type I protein.

L2 ANSWER 6 OF 6 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
AN 2002-138958 [18] WPIDS
AB US2002009489 A UPAB: 20020319
NOVELTY - A method and kit for treating atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders, by administering an **MC148P** protein (specifically MC148P1, MC148P2, MC148P3), are new. **MC148P** Proteins are derived from Molluscum Contagiosum Virus.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:
(1) a method (I), comprising administering, to a patient having atopic dermatitis, a composition comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity; and
(2) a kit (II), comprising multiple separately packaged portions of a composition adapted for treating atopic dermatitis comprising a **MC148P** protein which possesses atopic dermatitis inhibiting activity.
ACTIVITY - Dermatological; anti-allergic; anti-inflammatory; anti-asthmatic.
No quantitative biological data given.
MECHANISM OF ACTION - None given.
USE - The **MC148P** protein is administered to treat atopic dermatitis, other atopic diseases and other inflammatory and/or allergic skin disorders (claimed).
Dwg.0/5
ACCESSION NUMBER: 2002-138958 [18] WPIDS
DOC. NO. CPI: C2002-042742
TITLE: Treating atopic dermatitis, inflammations and allergic skin disorders by administering **MC148P** proteins from Molluscum Contagiosum Virus.
DERWENT CLASS: B04 D16
INVENTOR(S): PASLIN, D A
PATENT ASSIGNEE(S): (PASL-I) PASLIN D A
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002009489	A1	20020124	(200218)*		15

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002009489 A1	Cont of	US 1999-426093	19991022
	Cont of	US 2000-624748	20000724
		US 2001-920897	20010801

PRIORITY APPLN. INFO: US 1999-426093 19991022; US 2000-624748 20000724; US 2001-920897 20010801

=> d his

(FILE 'HOME' ENTERED AT 08:16:39 ON 05 DEC 2003)

```
     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS' ENTERED AT 08:17:09 ON 05 DEC 2003
L1         62880 S ATOPIC DERMATITIS
L2             6 S MC148P

=> s l1 and treatment
L3         17364 L1 AND TREATMENT

=> s molluscum contagiosum virus or MCV
L4          7261 MOLLUSCUM CONTAGIOSUM VIRUS OR MCV

=> s l4 and l3
L5            18 L4 AND L3

=> d l5 ti abs ibib tot

L5   ANSWER 1 OF 18     MEDLINE on STN
TI   [Atopic dermatitis and pox-virus superinfections
     (author's transl)].
     Dermatite atopique et surinfection a pox-virus.
AB   Subjects afflicted with atopic dermatitis are
     particularly predisposed to such viral superinfections as verruca, herpes
     (eczema herpeticum) and vaccinia (eczema vaccinatum). Knowledge of
     superinfection by the molluscum contagiosum
     virus is more recent and the authors describe one case. The orf
     virus (responsible for ovine ecthyma contagiosum), however, has never been
     described as responsible for the profuse superinfection of an atopic
     eczema. The authors observed one case of this in a child, atypical as
     result of his age (16 months), the cervical localization and the aspect,
     which was a telangiectasic granuloma type of the initial element, and
     finally of the satellization observed one week later. This child suffered
     from a generalized atopic eczema. Propagation of the orf lesions could
     have been favored by scratching, local corticoid treatment and
     by the deficit in cellular immunity observed in patient with
     atopic dermatitis. Indeed, viral superinfections, which
     are unusual by their profusion or their chronic nature, are often observed
     in immunodepressed subjects.
ACCESSION NUMBER:   82111890     MEDLINE
DOCUMENT NUMBER:    82111890   PubMed ID: 6275765
TITLE:              [Atopic dermatitis and pox-virus
                    superinfections (author's transl)].
                    Dermatite atopique et surinfection a pox-virus.
AUTHOR:             Dupre A; Christol B; Lassere J
SOURCE:             ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, (1981) 108 (11)
                    829-34.
                    Journal code: 7702013. ISSN: 0151-9638.
PUB. COUNTRY:       France
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           French
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        198203
ENTRY DATE:         Entered STN: 19900317
                    Last Updated on STN: 19900317
                    Entered Medline: 19820313

L5   ANSWER 2 OF 18  USPATFULL on STN
TI     Preventive or therapeutic agent for pollen allergy, allergic rhinitis,
       atopic dermatitis, asthma or urticaria, or health food
       for prevention or improvement or reduction of symptoms thereof
AB     A method for prevention or therapy of pollen allergy, allergic rhinitis,
       atopic dermatitis, asthma or urticaria by
       administration of two kinds of crude drugs--seeds of Cucurbita moschata
       and flowers of Carthamus tinotorius--and at least one crude drug
       selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza
```

uralensis, Coix lachrymal-jobi var, ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.

ACCESSION NUMBER: 2003:282356 USPATFULL
TITLE: Preventive or therapeutic agent for pollen allergy, allergic rhinitis, **atopic dermatitis** , asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
INVENTOR(S): Yoshida, Satoshi, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198697	A1	20031023
APPLICATION INFO.:	US 2002-126779	A1	20020422 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 800

L5 ANSWER 3 OF 18 USPATFULL on STN
TI Compounds and methods for modulating CXCR3 function
AB Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:174006 USPATFULL
TITLE: Compounds and methods for modulating CXCR3 function
INVENTOR(S): Schall, Thomas J., Palo Alto, CA, UNITED STATES
Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
McMaster, Brian E., Mountain View, CA, UNITED STATES
PATENT ASSIGNEE(S): ChemoCentryx, Inc., San Carlos, CA, UNITED STATES, 94070 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119854	A1	20030626
APPLICATION INFO.:	US 2002-279353	A1	20021023 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-648329, filed on 25 Aug 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151212P	19990827 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 18 USPATFULL on STN
TI Compounds and methods for modulating cxcr3 function
AB The invention provides compounds and compositions of the formula: ##STR1##

wherein

the subscript n is an integer of from 0 to 4;

Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R.sup.1 is a member selected from the group consisting of substituted or unsubstituted (C.sub.5-C.sub.15)alkyl;

R.sup.2 is a member selected from the group consisting of substituted or unsubstituted (C.sub.1-C.sub.8)alkyl;

each R.sup.3 is independently a substituent selected from -halogen, --OR', --OC(O)R', --NR'R", --SR', --R', --CN, --NO.sub.2, --CO.sub.2R', --CONR'R", --C(O)R', --OC(O)NR'R", --NR"C(O)R', --NR"C(O).sub.2R', , --NR'--C(O)NR"R'", --NH--C(NH.sub.2).dbd.NH, --NR'C(NH.sub.2).dbd.NH, --NH--C(NH.sub.2).dbd.NR--, --S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R", --N.sub.3, --CH(Ph).sub.2, perfluoro(C.sub.1-C.sub.4)alkoxy, and perfluoro(C.sub.1-C.sub.4)alkyl, and where R', R" and R'" are independently selected from hydrogen, (C.sub.1-C.sub.8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and (unsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl;

Y is a member selected from the group consisting of substituted or unsubstituted (C.sub.2-C.sub.8)alkylene and substituted or unsubstituted (C.sub.2-C.sub.8)heteroalkylene;

and Z is --NR.sup.4R.sup.5, wherein R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen and (C.sub.1-C.sub.8)alkyl.

These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, infectious disease, angiogenesis, and graft rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:123349 USPATFULL
TITLE:	Compounds and methods for modulating cxcr3 function
INVENTOR(S):	Schall, Thomas J., Palo Alto, CA, United States Dairaghi, Daniel J., Palo Alto, CA, United States McMaster, Brian E., Mountain View, CA, United States
PATENT ASSIGNEE(S):	Chemocentryx, Inc., San Carlos, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6559160	B1	20030506	
APPLICATION INFO.:	US 2000-648329		20000825	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-151212P	19990827	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Habte, Kahsay
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 18 USPATFULL on STN
TI Blood cell deficiency **treatment** method
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the **treatment** method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:120747 USPATFULL
TITLE:	Blood cell deficiency **treatment** method
INVENTOR(S):	Ahlem, Clarence N., San Diego, CA, UNITED STATES Reading, Christopher, San Diego, CA, UNITED STATES Frincke, James, San Diego, CA, UNITED STATES Stickney, Dwight, Granite Bay, CA, UNITED STATES Lardy, Henry A., Madison, WI, UNITED STATES Marwah, Padma, Middleton, WI, UNITED STATES Marwah, Ashok, Middleton, WI, UNITED STATES Prendergast, Patrick T., Straffan, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083231	A1	20030501
APPLICATION INFO.:	US 2002-87929	A1	20020301 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-161453P	19991025 (60)
	US 2001-272624P	20010301 (60)
	US 2001-323016P	20010911 (60)
	US 2001-340045P	20011130 (60)
	US 2001-328738P	20011011 (60)
	US 2001-338015P	20011108 (60)
	US 2001-343523P	20011220 (60)
	US 1999-126056P	19991019 (60)
	US 1999-124087P	19990311 (60)
	US 1998-109923P	19981124 (60)
	US 1998-109924P	19981124 (60)
	US 1998-110127P	19981127 (60)
	US 1998-112206P	19981215 (60)
	US 1999-145823P	19990727 (60)
	US 1999-137745P	19990603 (60)

	US 1999-140028P 19990616 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
LINE COUNT:	19428

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 18 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the **treatment** of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the **treatment** of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:100123 USPATFULL
TITLE:	CXCR3 antagonists
INVENTOR(S):	Medina, Julio C., San Carlos, CA, UNITED STATES Johnson, Michael G., San Francisco, CA, UNITED STATES Li, An-Rong, So. San Francisco, CA, UNITED STATES Liu, Jiwen, Belmont, CA, UNITED STATES Huang, Alan Xi, San Mateo, CA, UNITED STATES Zhu, Liusheng, Burlingame, CA, UNITED STATES Marcus, Andrew P., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003069234	A1	20030410	
APPLICATION INFO.:	US 2002-164690	A1	20020606	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-296499P	20010606	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Pennie & Edmonds, LLP, 3300 Hillview Avenue, Palo Alto, CA, 94304
NUMBER OF CLAIMS:	135
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Page(s)
LINE COUNT:	5271

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 18 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the **treatment** of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the **treatment** of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:79127 USPATFULL
TITLE:	CXCR3 antagonists
INVENTOR(S):	Medina, Julio C., San Carlos, CA, UNITED STATES Johnson, Michael G., San Francisco, CA, UNITED STATES

Li, An-Rong, So. San Francisco, CA, UNITED STATES
Liu, Jiwen, Belmont, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
Marcus, Andrew P., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055054	A1	20030320
APPLICATION INFO.:	US 2002-231895	A1	20020829 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-15532, filed on 11 Dec 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255241P	20001211 (60)
	US 2001-296499P	20010606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 135
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 5270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 18 USPATFULL on STN
TI Apoptosis related polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:71447 USPATFULL
TITLE: Apoptosis related polynucleotides, polypeptides, and antibodies
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049732	A1	20030313
APPLICATION INFO.:	US 2001-13477	A1	20011213 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-669445, filed on 25 Sep 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US6642, filed on 15 Mar 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126018P	19990324 (60)
	US 1999-139638P	19990617 (60)
	US 1999-149449P	19990818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 12594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 18 USPATFULL on STN
TI Agent for the anti-adhesion of skin pathogenic flora
AB Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.

ACCESSION NUMBER: 2003:70946 USPATFULL
TITLE: Agent for the anti-adhesion of skin pathogenic flora
INVENTOR(S): Baur, Markus, Stuttgart, GERMANY, FEDERAL REPUBLIC OF
Zink, Ralf, Le Mont Pelerin, SWITZERLAND
Auzanneau, Isabelle, Opio, FRANCE
Buffard, Karine, Sevres, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049231	A1	20030313
APPLICATION INFO.:	US 2002-177589	A1	20020621 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP12719, filed on 13 Dec 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-204489	19991222

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 833

L5 ANSWER 10 OF 18 USPATFULL on STN
TI Ccr4 antagonists
AB Compounds, compositions and methods are provided that are useful in the **treatment** of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the **treatment** or prevention of inflammatory conditions and diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:24179 USPATFULL
TITLE: Ccr4 antagonists
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
Mahmud, Hossen, San Antonio, TX, UNITED STATES
Houze, Jonathan, San Mateo, CA, UNITED STATES
Huang, Alan Xi, San Mateo, CA, UNITED STATES
Medina, Julio C., San Carlos, CA, UNITED STATES
Wang, Xuemei, San Mateo, CA, UNITED STATES
Xu, Feng, Palo Alto, CA, UNITED STATES
Xu, Qingge, Burlingame, CA, UNITED STATES
Zhu, Liusheng, Burlingame, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018022	A1	20030123
APPLICATION INFO.:	US 2002-155605	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293781P	20010523 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Tularik Inc., Two Corporate Drive, So. San Francisco, CA, 94080
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 18 USPATFULL on STN
TI Modulation of CCR4 function
AB Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:308398 USPATFULL
TITLE: Modulation of CCR4 function
INVENTOR(S): Collins, Tassie, San Mateo, CA, UNITED STATES
Dairaghi, Daniel J., Palo Alto, CA, UNITED STATES
Mahmud, Hossen, San Antonio, TX, UNITED STATES
McMaster, Brian E., Mountain View, CA, UNITED STATES
Medina, Julio C., San Carlos, CA, UNITED STATES
Schall, Thomas J., Palo Alto, CA, UNITED STATES
Xu, Feng, Palo Alto, CA, UNITED STATES
Wang, Xuemei, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Tularik Inc., So. San Francisco, CA, UNITED STATES, 94080 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002173524	A1	20021121
APPLICATION INFO.:	US 2001-975566	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240022P	20001011 (60)
	US 2001-293781P	20010523 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 84
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 18 USPATFULL on STN
TI CXCR3 antagonists
AB Compounds, compositions and methods that are useful in the **treatment** of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the **treatment** of inflammatory

and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:301614 USPATFULL
TITLE:	CXCR3 antagonists
INVENTOR(S):	Medina, Julio C., San Carlos, CA, UNITED STATES Johnson, Michael G., San Francisco, CA, UNITED STATES Li, An-Rong, So. San Francisco, CA, UNITED STATES Liu, Jiwen, Belmont, CA, UNITED STATES Xi Huang, Alan, San Mateo, CA, UNITED STATES Zhu, Liusheng, Burlingame, CA, UNITED STATES Marcus, Andrew P., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S):	Tularik Inc., San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002169159	A1	20021114	
APPLICATION INFO.:	US 2001-15532	A1	20011211	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-255241P	20001211	(60)
	US 2001-296499P	20010606	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS:	135
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Page(s)
LINE COUNT:	5284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 18 USPATFULL on STN

TI Method of inhibiting stenosis and restenosis

AB The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD 18 or CCR2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:198275 USPATFULL
TITLE:	Method of inhibiting stenosis and restenosis
INVENTOR(S):	Horvath, Christopher J., Taunton, MA, UNITED STATES Rao, Patricia E., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002106369	A1	20020808	
APPLICATION INFO.:	US 2001-809739	A1	20010315	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-528267, filed on 17 Mar 2000, ABANDONED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Page(s)
LINE COUNT: 2234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 18 USPATFULL on STN
TI **Atopic dermatitis treatment** method
AB Compositions are provided for treating **atopic dermatitis**, other atopic diseases and other inflammatory or allergic skin disorders. The compositions include proteins from **Molluscum Contagiosum Virus** (**MCV**), or fragments, variants, analogs, and derivatives thereof which exhibit AD inhibiting activity. Examples of **MCV** proteins which exhibit AD inhibiting activity include MC148P1, MC148P2, MC148P3, other MC148P type proteins, and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, MC148P3, and other MC148P type-proteins which possess AD inhibiting activity. The fragments, variants, analogs and derivatives may be less than 100 % homologous to **MCV** proteings so long as they are sufficiently homologous such that AD inhibiting activity is preserved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:16613 USPATFULL
TITLE: **Atopic dermatitis treatment** method
INVENTOR(S): Paslin, David A., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009489	A1	20020124
APPLICATION INFO.:	US 2001-920897	A1	20010801 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-624748, filed on 24 Jul 2000, PENDING Continuation of Ser. No. US 1999-426093, filed on 22 Oct 1999, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 18 USPATFULL on STN
TI Therapeutic agent and method for feline AIDS virus infections and feline **atopic dermatitis**
AB A therapeutic agent for feline immunodeficiency virus (FIV) infections, (including the **treatment** of the anemia and chronic stomatitis caused by infection with a FIV) comprising a feline interferon preparation containing a feline interferon as a principal agent, and a therapeutic method for FIV infections comprising administering a feline interferon preparation containing a feline interferon as a principal agent to a cat every day are disclosed. Furthermore, a therapeutic method and agent for feline **atopic dermatitis** are disclosed. The preferred feline interferon, is an .omega.-feline interferon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:29533 USPATFULL
TITLE: Therapeutic agent and method for feline AIDS virus

infections and feline **atopic dermatitis**

INVENTOR(S): Kajimoto, Tsunesuke, Kanagawa, Japan
Go, Ryougai, Houston, TX, United States
Suzuki, Makoto, Aichi, Japan

PATENT ASSIGNEE(S): Toray Industries, Inc., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6194381	B1	20010227	
	WO 9818484		19980507	
APPLICATION INFO.:	US 1998-101144		19981119	(9)
	WO 1997-JP3963		19971030	
			19981119	PCT 371 date
			19981119	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-290601	19961031

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Miller, Austin R.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 18 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Azathioprine in dermatological practice: An overview with special emphasis on its use in non-bullous inflammatory dermatoses.

AB Azathioprine is employed for its immunosuppressive properties, as a steroid-sparing agent or as monotherapy. Its most traditional clinical indications are connective tissue diseases, vasculitis, post-transplant, and immunobullous dermatoses. The main disadvantages of azathioprine therapy are a delayed onset of action (6-8 weeks), and rare profound bone marrow toxicity. Susceptibility to bone marrow toxicity is due to a genetically determined metabolic defect (1 in 300). Patients at risk of such toxicity may be identified by a Thiopurine methyltransferase enzyme assay. We have undertaken a retrospective study, looking at the use of azathioprine as monotherapy for non-bullous inflammatory, dermatoses. We studied a total of 24 patients (10 male, 14 female). The dermatoses comprised: atopic eczema (10), pompholyx (6), plaque psoriasis (6), and chronic actinic dermatitis (2). All patients had severe refractory disease warranting systemic second line therapy. The mean age was 49.4 years (range 17-86 years). The starting dose of azathioprine was 100-150 mg/day, and the maintenance dose 50-100 mg/day. The mean duration of **treatment** was 33.5 months (range 1-132 months). Eighteen patients (75%) showed a good to excellent sustained clinical response to azathioprine. This response rate was evenly represented in the 4 dermatoses studied. The adverse reactions encountered were raised **MCV** (6), leucopenia (2), raised hepatic enzymes (6), and dyspepsia (4). Azathioprine had to be discontinued due to adverse reactions in 2 patients (dyspepsia, raised hepatic enzymes) followed by normalisation. Other factors that potentially contributed to the observed adverse events were present in 5 patients: alcoholism (2), erythromycin toxicity (1), and malabsorption (2). Our study demonstrates the efficacy of azathioprine monotherapy for severe atopic eczema, pompholyx, plaque psoriasis, and chronic actinic dermatitis. Furthermore, azathioprine is a low cost and generally well tolerated drug.

ACCESSION NUMBER: 2001088570 EMBASE
TITLE: Azathioprine in dermatological practice: An overview with

special emphasis on its use in non-bullous inflammatory dermatoses.
AUTHOR: Scerri L.
CORPORATE SOURCE: L. Scerri, Sir Paul Boffa Hospital, Floriana, Malta
SOURCE: Advances in Experimental Medicine and Biology, (1999) 455/- (343-348).
Refs: 11
ISSN: 0065-2598 CODEN: AEMBAP
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 013 Dermatology and Venereology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

L5 ANSWER 17 OF 18 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI [**Atopic dermatitis** and pox-virus superinfections].
DERMATITE ATOPIQUE ET SURINFECTION A POX-VIRUS.
AB Subjects afflicted with **atopic dermatitis** are particularly predisposed to such viral superinfections as verruca, herpes (eczema herpeticum) and vaccinia (eczema vaccinatum). Knowledge of superinfection by the **molluscum contagiosum virus** is more recent and the authors describe one case. The orf virus (responsible for ovine ecthyma contagiosum), however, has never been described as responsible for the profuse superinfection of an atopic eczema. The authors observed one case of this in a child which was considered atypical because of his age (16 months), the cervical localization and the aspect, which was a telangiectasic granuloma type of the initial element, and finally of the satellization observed one week later. This child suffered from a generalized atopic eczema. Propagation of the orf lesions could have been favored by scratching, local corticoid **treatment** and by the deficit in cellular immunity observed in patients with **atopic dermatitis**. Indeed, viral superinfections, which are unusual by their profusion or their chronic nature, are often observed in immunodepressed subjects.
ACCESSION NUMBER: 82058467 EMBASE
DOCUMENT NUMBER: 1982058467
TITLE: [**Atopic dermatitis** and pox-virus superinfections].
DERMATITE ATOPIQUE ET SURINFECTION A POX-VIRUS.
AUTHOR: Dupre A.; Christol B.; Lassere J.
CORPORATE SOURCE: Serv. Dermatol., Hop. La Grave, F-31052 Toulouse, France
SOURCE: Annales de Dermatologie et de Venereologie, (1981) 108/11 (829-834).
CODEN: ADVED7
COUNTRY: France
DOCUMENT TYPE: Journal
FILE SEGMENT: 013 Dermatology and Venereology
047 Virology
LANGUAGE: French
SUMMARY LANGUAGE: English

L5 ANSWER 18 OF 18 JICST-EPlus COPYRIGHT 2003 JST on STN
TI Informed Consent in the **Treatment** of Pediatric Surgical Diseases. (II). Molluscum Contagiosum.
AB Molluseum contagiosum(MC) is an infectious benign skin disease caused by mollucum contagiosum virus(**MCV**), which is a member of the human poxviruses. In the last decade, the number of patients with MC has increased as more children attend swimming schools is Japan. However, the effective **treatment** for MC is still surgical removal with blunt forceps, which unfortunately gives great pain. Therefore, the

establishment of a new therapeutic modality is needed. (author abst.)

ACCESSION NUMBER: 930607451 JICST-EPlus
TITLE: Informed Consent in the **Treatment** of Pediatric Surgical Diseases. (II). Molluscum Contagiosum.
AUTHOR: YAMASHITA HIROKO; KAWASHIMA MAKOTO
CORPORATE SOURCE: Tokyo Women's Medical College
SOURCE: Shoni Geka (Japanese Journal of Pediatric Surgery), (1993) vol. 25, no. 6, pp. 649-652. Journal Code: Z0323B (Fig. 3, Tbl. 1, Ref. 11)
ISSN: 0385-6313
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Commentary
LANGUAGE: Japanese
STATUS: New

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L7 and inotophoresis	2

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text | Clear

Search History

DATE: Friday, December 05, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L8	L7 and inotophoresis	2	L8
L7	L6 and dimethyl sulfoxide	54630	L7
L6	l4 and inhibition	2132	L6
L5	MC148P	0	L5
L4	L3 and treatment	2657	L4
L3	L2 and l1	2712	L3
L2	atopic dermatitis	8494	L2
L1	molluscum contagiosum virus or MCV	56886	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US RE38000 E

L8: Entry 1 of 2 File: USPT Feb 25, 2003

US-PAT-NO: RE38000
DOCUMENT-IDENTIFIER: US RE38000 E

TITLE: Electrokinetic drug delivery apparatus

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Henley; Julian L.	Guilford	CT		

US-CL-CURRENT: 604/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 2. Document ID: US 6048545 A

L8: Entry 2 of 2 File: USPT Apr 11, 2000

US-PAT-NO: 6048545
DOCUMENT-IDENTIFIER: US 6048545 A

TITLE: Liposomal delivery by iontophoresis

DATE-ISSUED: April 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keller; Brian C.	Antioch	CA		
Fisher; Daniel L.	Pleasant Hill	CA		
Kiss; Stefan	Concord	CA		
Mezei; Michael	Halifax			CA

US-CL-CURRENT: 424/450; 424/1.21, 424/401, 424/9.321, 424/9.51, 604/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

Generate Collection | Print

Terms	Documents
L7 and inotophoresis	2

Display Format: CIT Change Format

Previous Page Next Page

WEST

Generate Collection Print

L8: Entry 1 of 2 File: USPT Feb 25, 2003

DOCUMENT-IDENTIFIER: US RE38000 E
TITLE: Electrokinetic drug delivery apparatus

Other Reference Publication (11):
"The Quantity and Distribution of Radiolabeled Dexamethasone Delivered to Tissue by Inotophoresis," Glass et al.; International Journal of Dermatology, vol. 19, Nov. 1980, pp. 519-525.

Other Reference Publication (27):
"Early Application of Topical 15% Idoxuridine in Dimethyl Sulfoxide Shortens the Course of Herpes Simplex Labialis: A Multicenter Placebo-Controlled Trial," Spruance et al., The Journal of Infectious Diseases; 1990, 161; pp. 191-197.

WEST

End of Result Set

Generate Collection | Print

L8: Entry 2 of 2 File: USPT Apr 11, 2000

DOCUMENT-IDENTIFIER: US 6048545 A
TITLE: Liposomal delivery by iontophoresis

Detailed Description Text (31):
While not required to practice the method of the invention, permeability enhancers conventionally known in the art can also be present, usually about 1 to about 10% by w. Suitable permeability enhancers include fatty acid esters and fatty alcohol ethers of C.sub.1-4 alkanediols, alcohols such as ethanol, dimethyl sulfoxide, polyethylene glycol monolaurate and the like.

CLAIMS:

1. A method for administration of an substance selected from the group consisting of an uncharged dye and uncharged anesthetic to a subject comprising

applying directly to the skin or tissue of the subject a composition comprising said substance encapsulated within liposomes having either a positively or negatively charged surface by inotophoresis where the electric current is from about 1 to about 3 milliamperes and the duration is form about 1 to 15 minutes which causes dermal penetration.